# China Protection Trial of Glucose Metabolism by Pitavastatin in Patients With Prediabetes and Hypertension

Study · id `cardio:ct-nct03532620` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03532620](<https://clinicaltrials.gov/study/NCT03532620>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03532620

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 396 participants.

## Technical summary

Registry record NCT03532620. Randomized; no masking; primary purpose treatment. Start 2018-08-09 (actual); primary completion 2019-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 396 participants (planned count; ClinicalTrials.gov record NCT03532620, source copy `cardio:ctgov-nct03532620-2019-06-03`, retrieved 2026-10-26)
- Started: 2018-08-09 (actual) (ClinicalTrials.gov record NCT03532620, source copy `cardio:ctgov-nct03532620-2019-06-03`, retrieved 2026-10-26)
- Primary completion: 2019-09 (anticipated) (ClinicalTrials.gov record NCT03532620, source copy `cardio:ctgov-nct03532620-2019-06-03`, retrieved 2026-10-26)
- Completion: 2020-09 (anticipated) (ClinicalTrials.gov record NCT03532620, source copy `cardio:ctgov-nct03532620-2019-06-03`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03532620, source copy `cardio:ctgov-nct03532620-2019-06-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03532620-2019-06-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: China Protection Trial of Glucose Metabolism by Pitavastatin in Patients With Prediabetes and Hypertension
- Acronym: CAMPUS
- Condition: Prediabetic State
- Condition: Hypertension
- Condition: Dyslipidemias
- Intervention (Drug): Pitavastatin Calcium
- Intervention (Drug): Atorvastatin Calcium
- Lead sponsor: Jun Tao
- Lead sponsor class: OTHER
- Collaborator: Sun Yat-sen University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as a collaborator: Sun Yat-sen University (`cardio:org-sun-yat-sen-university`)

## Provenance

Content hash: 19b8681bbfcafa9e01c930331484da17b446b4a236785f75b390bd5d93f4f1ee
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
